



A Letter from the Founder, Dr. Christine Brezden-Masley

Thank you for supporting the CCTC throughout 2018. We look forward to providing you up-to-date clinical trials information that is seamless and fast. By increasing our provincial clinical trials enrollment, this has the potential to benefit patients and allow for more clinical trials to be considered in Canada.

If you have any concerns or improvements of the website, please let us know. Be sure to follow our twitter page [@COMET_Trials](https://twitter.com/COMET_Trials) for the latest updates regarding open trials.

Sincerely,
Dr. Christine Brezden-Masley

Hello everyone,

Please feel free to share this newsletter with any colleagues that may be interested, as we are always happy to have new members join our network!

For assistance in posting new trials, or if you would like to nominate an accruing trial to be featured in our *Trials of the Month*, please do not hesitate to contact me at cometrials@smh.ca

Kind Regards,

Alexandria Abbruzzino

ARTICLE RECOMMENDATION

Developing a model of a patient-group pathway to accessing cancer clinical trials in Canada.

Batist G, Michaud S, Richards DP, Servidio-Italiano F, Stein BD.
DOI: 10.3747/co.25.4213 Published Dec 1 2018

ABSTRACT:

Background:

Colorectal Cancer Canada, in partnership with a Scientific Advisory Committee, is developing a Canadian Patient Group Pathway to Accessing Cancer Clinical Trials ("Pathway"). A central element of the Pathway is presented here-namely, a set of recommendations and tools aimed at each stakeholder group.

Methods:

A summary of the peer-reviewed and grey literature informed discussions at a meeting, held in June 2017, in which a cross-section of stakeholders reached consensus on the potential roles of patient groups in the cancer clinical trials process, barriers to accessing cancer clinical trials, best practice models for patient-group integration, and a process for developing the Pathway. Canadian recommendations and tools were subsequently developed by a small working group and reviewed by the Scientific Advisory Committee.

Results:

The major output of the consensus conference was agreement that the Clinical Trials Transformation Initiative (ctti) model, successfully applied in the United States, could be adapted to create a Canadian Pathway. Two main differences between the Canadian and American cancer clinical research environments were highlighted: the effects of global decision-making and systems of regulatory and funding approvals. The working group modified the ctti model to incorporate those aspects and to reflect Canadian stakeholder organizations and how they currently interact with patient groups.

TRIALS SNAPSHOT

Trial Type	Any Malignancy	Breast	GI	GU	GYNE	Head & Neck	Heme	Lung	Mel	Skin	Total
Imaging Study		1		1			1				3
Observational	1	4	1	1			1				8
Prevention			1				1				2
Radiation	1	2	3	5		1		5			17
Supportive Care	1	4									4
Surgical Therapy		1		1	1	1					4
Systemic Therapy	4	8	17	15	5	3	16	6	3	1	79
Therapeutic				1			2				3
TOTAL	7	20	22	24	6	5	21	11	3	1	120



TRIALS OF THE MONTH


Type	Acronym	Study Title	Description	Site(s)
Breast	<u>Treater+ight</u>	Treatment of Canadian Postmenopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy	<ul style="list-style-type: none"> • HR+, HER2– advanced breast cancer • Treated with endocrine therapy (ET) or ET in combination with targeted therapy 	Cambridge Memorial Hospital Kingston General Hospital London Health Sciences Centre North York General Hospital Southlake Regional Health Centre St. Michael's Hospital
GU	<u>IND.234</u>	Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study	<ul style="list-style-type: none"> • Systemic Therapy • Prostate Cancer 	London Health Sciences Centre
Heme	<u>E1910</u>	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults	<ul style="list-style-type: none"> • combination chemotherapy with or without blinatumomab • Newly diagnosed 	Kingston General Hospital
Skin	<u>Regeneron BCC</u>	A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy (R2810-ONC-1620)	<ul style="list-style-type: none"> • Advanced Basal Cell Carcinoma • Progressed on hedgehog inhibitor therapy 	London Health Sciences Centre Odette Cancer Centre
Lung	<u>STOP-NSCLC</u>	Stereotactic Radiotherapy for Oligo-Progressive Non-Small Cell Lung Cancer (STOP-NSCLC): A Randomized Phase II Trial	<ul style="list-style-type: none"> • Non-small Cell Lung Cancer • Stereotactic Ablative Radiotherapy 	London Health Sciences Centre
GYNE	<u>GARENET</u>	A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors	<ul style="list-style-type: none"> • Endometrial/Uterine • Advanced (locally recurrent or metastatic) 	London Health Sciences Centre
GI	<u>CO28</u>	NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer	<ul style="list-style-type: none"> • Early Rectal cancer • Chemotherapy followed by less invasive surgery on patients • Neoadjuvant 	Kingston General Hospital





MEMBERSHIP UPDATES

285 members
29 institutions
121 accruing trials



ACKNOWLEDGEMENTS

The CCTC has been funded by unrestricted educational grants from the following supporters:



CONTACT US

Do you have any questions, feedback, suggestions? Please do not hesitate to contact us.

30 Bond Street
Toronto, ON Canada
M5B 1W8

cometrials@smh.ca
(416) 809-3915

@COMET_Trials
www.cometrials.com

INSTITUTIONS

Institution	Location	Members	Trials
Cambridge Memorial Hospital	Cambridge	3	2
Grand River Hospital	Waterloo	7	1
Humber River Regional Hospital	Toronto	5	1
Kingston General Hospital	Kingston	3	33
Juravinski Cancer Centre	Hamilton	6	-
Lakeridge Health Corporation	Oshawa	20	-
London Health Sciences Centre	London	11	51
Mackenzie Health Hospital	Richmond Hill	6	-
Markham Stouffville Hospital	Markham	4	-
Mount Sinai Hospital	Toronto	2	1
North York General Hospital	Toronto	14	4
Odette Cancer Centre/Sunnybrook	Toronto	63	52
Ontario Institute for Cancer Research	Toronto	4	-
Ottawa Hospital	Ottawa	2	-
Princess Margaret Cancer Centre	Toronto	25	1
Quinte Health Care	Belleville	1	-
Rouge Valley Health System	Ajax	3	-
Royal Victoria Regional Health Centre	Barrie	23	12
Scarborough General Hospital	Toronto	3	-
Southlake Regional Health Centre	Newmarket	20	5
St. Joseph's Health Centre	Toronto	3	-
St. Joseph's Healthcare	Hamilton	4	-
St. Michael's Hospital	Toronto	13	7
Sudbury Regional Hospital	Sudbury	1	-
Thunder Bay Regional	Thunder Bay	2	-
Toronto General Hospital	Toronto	3	1
Trillium Health Partners	Mississauga	18	4
William Osler Health Systems	Brampton	3	-
Windsor Regional Hospital	Windsor	2	-